Product
Supplier
Encyclopedia
Inquiry
Edoxaban Tosylate buy - large image1
Edoxaban Tosylate buy - image1
Edoxaban Tosylate buy - image2

Edoxaban Tosylate

GMP COA

Unit Price: Get Latest Price
CAS No.:

1229194-11-9

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Shanghai

Brand:

Simcere

Packaging:

5kg/Cardboard Drum

Price valid (until):

2025-01-31

Company Type:
Manufactory
Location:
China
Qualification:
Main Products:

Diosmectite,Bedaquiline FuMarate,Iguratimod,Edoxaban Tosylate,Edaravone,Borneol

  • Product Description

  • Seller Information

  • Description


      Product Detail  


    Anticoagulants
    On January 8, 2015, the U.S. FDA approved the anticoagulant drug Edoxaban (Savaysa) from Daiichi Sankyo Pharmaceutical Co., Ltd. of Japan. Edoxaban is a selective coagulation factor Xa inhibitor oral tablet for the prevention and treatment of deep vein thrombosis and pulmonary embolism, and is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). Currently, there are three specifications: 60mg, 30mg and 15mg.

    Biological activity
    Edoxaban (DU-176b) is a selective inhibitor of factor Xa and an anticoagulant drug with oral effect.

    Items Specifications
    Melting point  >252°C (dec.)
    form  Solid
    color  White to Off-White
    solubility  Chloroform (Very Slightly), DMSO (Slightly), Methanol (Slightly, Sonicated)

    Certificates

    Basic Info
    Product Name:

    N-(5-Chloropyridin-2-yl)-N′-((1S,2R,4S)-4-[(dimethyl amino)carbonyl]-2-[[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl)ethanediamide p-toluenesulfonate monohydrate

    Other Name:

    Ethanediamide,N1-(5-chloro-2-pyridinyl)-N2-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-,4-methylbenzenesulfonate,hydrate (1:1:1);N-(5-Chloropyridin-2-yl)-N′-((1S,2R,4S)-4-[(dimethyl amino)carbonyl]-2-[[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl)ethanediamide p-toluenesulfonate monohydrate;N-(5-Chloropyridin-2-yl)-N′-[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-[[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]ethanediamide mono(p-toluenesulfonate) monohydrate;Edoxaban tosylate hydrate;Edoxaban tosylate monohydrate

    CAS No.:

    1229194-11-9

    Molecular Formula:

    C24H30ClN7O4S.C7H8O3S.H2O

    InChIKeys:

    InChIKey=PSMMNJNZVZZNOI-SJILXJHISA-N

    Molecular Weight:

    738.2744

    Exact Mass:

    737.206848

    EC Number:

    1592732-453-0

    UNII:

    972203R4EW

    DSSTox ID:

    DTXSID60153788

    ATC Code:

    B01|B01AF03

    Categories:

    Blood System Drugs

    Characteristics
    PSA:

    229

    XLogP3:

    4.34050

    Hazard Identification

    Classification of the substance or mixture

    no data available

    GHS label elements, including precautionary statements

    Pictogram(s) no data available
    Signal word

    no data available

    Hazard statement(s)

    no data available

    Precautionary statement(s)
    Prevention

    no data available

    Response

    no data available

    Storage

    no data available

    Disposal

    no data available

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Diosmectite,Bedaquiline FuMarate,Iguratimod,Edoxaban Tosylate,Edaravone,Borneol

    Location:

    No. 109, Changfenghe Road, Jiangbei New District, Nanjing

    Payment Terms:

    100% TT in advance

    Average lead Time:

    30

    Total Annual Revenue:

    Above $100 million

    Total Employees:

    Above 1000

    Year of Establishment:

    2022

    Simcere Pharmaceutical Group Limited (2096.HK) is a pharmaceutical company driven by innovative R&D. We are committed to "providing today's patients with medicines of the future" across the following core therapeutic areas: oncology, central nervous system, autoimmunity and anti-infection. Furthermore, we are also actively expanding our presence in disease areas with significant clinical needs in the future.

    Our industry-leading capabilities and commitment to synergistic innovation have also enabled various strategic collaborations and we are seen as the partner of choice by innovative biopharmaceutical companies, medical institutes, and research teams in China and globally.
  • Country Product Purchase Quantity Date Posted
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.